CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 143 enrolled / 143 target
Drug / intervention
Lorazepam and fMRI +1 moredrug
Likely dose
Lorazepam and fMRI 0.01 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04004416
NCT04004416Phase 4CompletedHigh Momentum (1.9/mo)Completion was 16mo ago

Multi-modal Assessment of GABA Function in Psychosis

University of Michigan·interventional·Posted Jul 2, 2019·Updated Jun 17, 2026

In Brief

A Phase 4 clinical trial evaluating Placebo and fMRI and Lorazepam and fMRI for Schizophrenia and 6 related conditions. Completed, enrolled 143 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam. This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as psychosis which includes conditions like schizophrenia, schizoaffective disorder, and mood disorders like bipolar disorder). The study will also enroll eligible participants between the ages of 18 and 60 without any psychiatric illness to compare their brains. The study will require participants to have 3-4 sessions over a few weeks. The initial assessments (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the fMRI. During the fMRI, the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, vital signs will be taken, they will be asked to complete more qols, and women of childbearing potential will have a urine pregnancy test.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedJul 2, 2019
Enrollment StartJan 16, 2020
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7 years ago

Arms & Interventions

Healthy Controlsplacebo_comparator

Other: Placebo and fMRIDrug: Lorazepam and fMRI
Early Psychosis patientsexperimental

Other: Placebo and fMRIDrug: Lorazepam and fMRI
Schizophrenia or Schizoaffective disorder patientsexperimental

Other: Placebo and fMRIDrug: Lorazepam and fMRI
Bipolar disorder patientsexperimental

Other: Placebo and fMRIDrug: Lorazepam and fMRI

Interventions

Placebo and fMRIother

There will be two fMRIs done after the initial assessment and approximately 28 days apart. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. A dose of Placebo will be given approximately 80-90 minutes prior to entering the fMRI scanner. Participants will complete assessments (vitals, questionnaires) and an optional blood draw prior to having each fMRI. Participants will be asked to rate pleasant/unpleasant pictures during their initial assessment visit and to view them during the fMRI.

Lorazepam and fMRIdrug

There will be two fMRIs done after the initial assessment and approximately 28 days apart. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given approximately 80-90 minutes prior to entering the fMRI scanner. Participants will complete assessments (vitals, questionnaires) and optional blood draw prior to having each fMRI. Participants will be asked to rate pleasant/unpleasant pictures during their initial assessment visit and to view them during the fMRI.